Johnson & Johnson has brushed off investors’ concerns over the many lawsuits it is facing, saying its legal team will overcome the litigation issues that have dominated headlines over t
Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.